Tag: Cancer: Cervical
HPV Cervical CA Screening Cuts Odds of Later CIN3+ Diagnosis
Use of primary HPV testing results in significantly lower odds of CIN3+ compared with cytology testing
Good Evidence That HPV Vaccines Protect Against Cervical Precancer
High-certainty evidence for protection in adolescent girls and young women aged 15 to 26 years
Mortality Risk Persists for Cancer Tied to Prenatal DES Exposure
Women with DES-related clear-cell adenocarcinoma had 27-fold higher mortality at 10 to 34 years
Cervical Cancer Frequently Diagnosed After Age 65
Almost 20 percent of cervical cancer cases are diagnosed in women older than 65
Many Untreated CIN2 Lesions Regress Spontaneously
Regression of cervical intraepithelial neoplasia grade 2 lesions especially likely in younger women
Risk of ≥CIN3 Drops With Negative HPV, Cytology Co-Tests
Decrease in 5-year ≥CIN3 risks after each successive negative round of HPV, cytology co-testing
ASTRO: High-Dose Brachytherapy Effective With Four 7 Gy Fractions
Better tumor control than with two 9 Gy fractions among patients with locally advanced cervical cancer
USPSTF Backs Cervical Cancer Screening With Cytology or hrHPV
Recommendations for screening with cytology alone every three years or hrHPV testing every five years
Cervical CA Survivors Often Have Long-Term Fatigue, Insomnia
Symptoms could have a serious impact on patients' daily lifes
First-Void Morning Urine Not Necessary for CIN2+ Detection
First-void urine also similar to physician-taken smears or brush-based self-samples
